Baxter: Investor Conference (Baxter) - May 23, 2015 - “Positive POC For SM101 In Systemic Lupus Erythematosus (SLE)”; “Overall Response At 24 Weeks (All Patients)”; “SLE responder index is composite endpoint based on: Overall Responder included SLEDAI, BILAG and PGA scores, The SLE responder index was primary endpoint in the Belimumab (Benlysta) pivotal studies”
P2a data • Lupus
|